mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFujian Provincial Hospital
About this trial
This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.
Eligibility criteria
Qualifiers
Fully understand this study and voluntarily sign the informed consent form;
Age between 18 and 75 years inclusive, with no gender restrictions;
Patients with locally advanced or metastatic pancreatic cancer diagnosed by histology or cytology;
No prior anti-cancer treatment;
Disqualifiers
Have already received or are currently receiving additional anti-tumor treatment measures such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine treatment;
Known allergies to any of the drugs in the study;
Symptomatic brain metastases or metastases with symptom control time less than 2 months;
A large liver metastasis burden, occupying more than 70% of the liver volume;
Trial design
Treatments tested in this trial
- Anlotinib combined with Sintilimab
Treatment groups
29 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov